Enlivex Therapeutics (NASDAQ:ENLV) Earns “Buy” Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of Enlivex Therapeutics (NASDAQ:ENLV) in a research note released on Friday morning,Benzinga reports. They currently have a $13.00 target price on the stock.

Enlivex Therapeutics Stock Up 6.8 %

Shares of Enlivex Therapeutics stock opened at $1.10 on Friday. Enlivex Therapeutics has a twelve month low of $0.81 and a twelve month high of $4.59. The company has a market cap of $23.55 million, a price-to-earnings ratio of -1.12 and a beta of 0.99. The company’s 50 day moving average is $1.18 and its 200 day moving average is $1.28.

Enlivex Therapeutics (NASDAQ:ENLV) last released its quarterly earnings results on Friday, November 29th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.04. Sell-side analysts expect that Enlivex Therapeutics will post -0.7 EPS for the current fiscal year.

Institutional Investors Weigh In On Enlivex Therapeutics

A hedge fund recently bought a new position in Enlivex Therapeutics stock. Sigma Investment Counselors Inc. bought a new stake in shares of Enlivex Therapeutics Ltd. (NASDAQ:ENLV) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 30,000 shares of the company’s stock, valued at approximately $50,000. Sigma Investment Counselors Inc. owned about 0.14% of Enlivex Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 1.02% of the company’s stock.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.